Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC.
Antigens, Neoplasm
/ metabolism
Bile Duct Neoplasms
/ diagnosis
Bile Ducts, Intrahepatic
Carcinoma, Hepatocellular
/ diagnosis
Cholangiocarcinoma
/ diagnosis
Diagnosis, Differential
Female
Humans
Immunohistochemistry
Integrins
/ metabolism
Klatskin Tumor
/ diagnosis
Liver Diseases
/ diagnosis
Liver Neoplasms
/ diagnosis
Male
Middle Aged
Molecular Imaging
Optical Imaging
Positron Emission Tomography Computed Tomography
Tissue Array Analysis
Cholangiocarcinoma
Diagnostic tool
Immunohistochemistry
Integrin
Molecular imaging
Journal
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
20
04
2020
revised:
05
09
2020
accepted:
21
09
2020
pubmed:
19
10
2020
medline:
15
9
2021
entrez:
18
10
2020
Statut:
ppublish
Résumé
Approximately 15% of patients undergoing resection for presumed perihilar cholangiocarcinoma (PHC) have benign disease at final pathological assessment. Molecular imaging targeting tumor-specific biomarkers could serve as a novel diagnostic tool to reduce these futile surgeries. Imaging agents have been developed, selectively binding integrin α Three tissue microarrays (TMA) including 103 PHC tumor cores and sixty tissue samples were selected from resection specimens of pathologically proven PHC (n = 20), ICC (n = 10), HCC (n = 10), metastatic PHC lymph nodes (n = 10) and benign disease (presumed PHC with benign disease at pathological assessment, n = 10). These samples were stained for integrin α Immunohistochemical staining for integrin α Integrin α
Sections du résumé
BACKGROUND
Approximately 15% of patients undergoing resection for presumed perihilar cholangiocarcinoma (PHC) have benign disease at final pathological assessment. Molecular imaging targeting tumor-specific biomarkers could serve as a novel diagnostic tool to reduce these futile surgeries. Imaging agents have been developed, selectively binding integrin α
MATERIALS & METHODS
Three tissue microarrays (TMA) including 103 PHC tumor cores and sixty tissue samples were selected from resection specimens of pathologically proven PHC (n = 20), ICC (n = 10), HCC (n = 10), metastatic PHC lymph nodes (n = 10) and benign disease (presumed PHC with benign disease at pathological assessment, n = 10). These samples were stained for integrin α
RESULTS
Immunohistochemical staining for integrin α
CONCLUSION
Integrin α
Identifiants
pubmed: 33069505
pii: S0748-7983(20)30798-8
doi: 10.1016/j.ejso.2020.09.026
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Integrins
0
integrin alphavbeta6
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
628-634Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.